The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Lytenava
bevacizumab-vikg · BEVACIZUMAB 1.25 mg/1 · Injection · Intravitreal · Outlook Therapeutics, Inc.
NDC 82491-0025-10 · 1 VIAL, GLASS in 1 CARTON / 1 INJECTION in 1 VIAL, GLASS · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761320
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of bevacizumab-vikg (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Outlook Therapeutics, Inc. | BEVACIZUMAB 1.25 mg/1 | Aug 7, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Lytenava — NDC 82491-0025-10," retrieved September 3, 2026, https://drugdashboards.com/drug/82491002510.
Free to cite with attribution — see how the data is put together.